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Abstract: The analysis and interpretation of high-throughput datasets relies on access to high-quality
bioinformatics resources, as well as processing pipelines and analysis tools. Gene Ontology
(GO, geneontology.org) is a major resource for gene enrichment analysis. The aim of this project,
funded by the Alzheimer’s Research United Kingdom (ARUK) foundation and led by the University
College London (UCL) biocuration team, was to enhance the GO resource by developing new
neurological GO terms, and use GO terms to annotate gene products associated with dementia.
Specifically, proteins and protein complexes relevant to processes involving amyloid-beta and tau
have been annotated and the resulting annotations are denoted in GO databases as ‘ARUK-UCL’.
Biological knowledge presented in the scientific literature was captured through the association of
GO terms with dementia-relevant protein records; GO itself was revised, and new GO terms were
added. This literature biocuration increased the number of Alzheimer’s-relevant gene products that
were being associated with neurological GO terms, such as ‘amyloid-beta clearance’ or ‘learning
or memory’, as well as neuronal structures and their compartments. Of the total 2055 annotations
that we contributed for the prioritised gene products, 526 have associated proteins and complexes
with neurological GO terms. To ensure that these descriptive annotations could be provided for
Alzheimer’s-relevant gene products, over 70 new GO terms were created. Here, we describe how the
improvements in ontology development and biocuration resulting from this initiative can benefit the
scientific community and enhance the interpretation of dementia data.
Keywords: Alzheimer’s disease; dementia; cognitive impairment; neurodegeneration; Gene Ontology;
annotation; biocuration; amyloid-beta; microtubule-associated protein tau
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1. Introduction
Understanding the cellular bases of Alzheimer’s disease (AD) and other dementias is an
essential step in helping develop improved therapies for their treatment and prevention, as well
as supporting early diagnosis. Although several genes associated with monogenic AD have been
identified [1], the majority of cases are likely to be due to multiple genetic, as well as environmental,
risk factors [2,3]. In order to understand the cellular processes and risk factors associated with AD
and other dementias, numerous transcriptomic, proteomic, and genome-wide association (GWA)
studies have been conducted [2,4–6]. Analyses and the interpretation of such high-throughput datasets
rely on high-quality annotations describing the biological roles of the implicated gene products,
as well as appropriate methodologies being used to generate the data, the application of appropriate
statistical methods, and implementation in analysis tools [4,6–8]. Gene annotation provides functional
knowledge of gene products (proteins and RNAs) in a format that can be fully exploited by systems
biology and genomic investigators. Thus, annotation resources bridge the gap between data collection
and data analysis [4,9]. The main resources used to identify significantly enriched pathways in
GWA, proteomic, and transcriptomic studies are those provided by the Gene Ontology (GO) [10],
Reactome [11], KEGG [12], and molecular interaction databases [13,14]. This data is imported into
independent enrichment analysis tools, such as g:Profiler [15], VLAD [16], or DAVID [17], which can
provide different enrichment options and/or settings, and are updated with different frequencies,
all of which will affect analyses’ outcomes.
The GO resource is a biomedical ontology that describes the physiological functional attributes of
gene products, across all species, in a consistent and computer-accessible manner using a controlled
vocabulary that facilitates the integration of public biological data [10,18,19]. Fully defined GO terms
are associated with gene products across many species, providing a computable summary of individual
experiments that demonstrate functional information (Figure 1). These links between GO terms and
gene products are known as ‘annotations’, and enable the description of gene products according to
their molecular functions (e.g., ‘scavenger receptor activity’), the biological processes they contribute
towards (e.g., ‘microtubule cytoskeleton organisation’), and their subcellular locations (or cellular
components, e.g., ‘extracellular region’) [10].
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Figure 1. A selection of Gene Ontology (GO) annotations created by Alzheimer’s Research United 
Kingdom (ARUK) – University College London (UCL), as a part of our project that focused on 
capturing knowledge on amyloid-beta and tau by the expert biocuration of experimental data 
available through the biomedical literature. These annotations describe related biological processes 
using GO terms, which are descendants of the ‘neuron projection development’ GO term. We created 
13 and revised two of the 24 GO terms in this branch. We created a total of 50 new annotations using 
these new neurological GO terms (Results sections: Revisions and development of neuron projection 
GO branches; Figure 4). ‘Symbol’ corresponds to the HUGO Gene Nomenclature Committee 
(HGNC)-approved gene symbol [20] encoding the gene product being annotated; the ‘GO Term’ 
section provides the GO identifier and term name; the ‘Reference’ column lists the source of the data 
supporting the annotation; this may be the curated article or information about the electronic 
annotation pipeline. The ‘Taxon’ column describes the species of origin of the protein being 
annotated; and the ‘Assigned By’ column shows that these annotations resulted from this project 
(Screenshot from QuickGO—accessed: 31 October 2018). 
One of the key advantages of the GO resource is that it can describe a protein’s likely role in a 
process or its probable location in a cell, even when its actual functional roles are still under 
investigation. For instance, GO will capture the role of a protein kinase in a signalling cascade even 
when the step in this cascade at which the enzyme is acting has not yet been fully elucidated. In 
contrast, Reactome and KEGG provide more ‘specific’ information about the role of a protein within 
a pathway by creating networks where the details of each ‘reaction’ being catalysed or facilitated are 
provided [11,12]. Consequently, proteins whose roles have not been fully elucidated cannot be 
included in these databases. However, occasionally Reactome will capture ‘BlackBox’ events when 
not all of the steps in a pathway are known [11]. In summary, Reactome provides annotations for 
10,800 human proteins, whereas GO provides manual annotations for 20,000 human proteins (data 
from QuickGO and Reactome, accessed: 20 August 2018). A common strength of all of these 
resources is that for any curated model organism, data can be conservatively mapped across to their 
human (and other species) orthologs; however, because many gene products are involved in 
multiple cellular processes, the comprehensive annotation of all gene products has not been 
achieved. Furthermore, although human and mammalian phenotype ontologies (HPO, MP) are 
being used to interpret next generation sequencing (NGS) data [21], understanding how multiple 
genes contribute to a single disease or phenotype will require resources, such as GO, that describe 
the cellular functions of these gene products. 
Amyloid-beta fibril deposits commonly known as plaques, and neurofibrillary tangles of 
phosphorylated tau, have for decades been the pathological hallmarks of Alzheimer’s disease [22]. 
For many years, researchers have been studying the formation and the effects of these protein 
aggregates on brain function [23–26]. However, much less attention and fewer resources have been 
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two of the 24 GO terms in this branch. We created a total of 50 new annotations using these new
neurological GO terms (Results sections: Revisions and development of neuron projection GO branches;
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gene symbol [20] encoding the g ne product b ing annotat d; the ‘GO Term’ section provides the
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One of the key adv tages of the GO r s urce is that it can describe a protein’s likely role
in a proc ss or its probable location in a c ll, even whe its actual functional roles are still under
investigation. For instance, GO will capture the role of a protein kinase in a signalling cascade
even when the step in this cascade at which the enzyme is acting has not yet been fully elucidated.
In contrast, Reactome and KEGG provide more ‘specific’ information about the role of a protein within
a pathway by creating networks where the details of each ‘reaction’ being catalysed or facilitated
are provided [11,12]. Consequently, prote ns whose roles have not been f lly elucidate cannot be
included in these databases. However, occasionally Reactome will capture ‘BlackBox’ events when
not all of the steps in a pathway are known [11]. In summary, Reactome provides annotations for
10,800 human proteins, whereas GO provides manual annotations for 20,000 human proteins (data from
QuickGO and Reactome, accessed: 20 August 2018). A common strength of all of these resources
is that for any curated model organism, data can be conservatively mapped acr ss to their human
(and other pecies) or hologs; howev r, because many gene p od cts are involved in multiple cellular
processes, the comprehensive annotation of all gene products has not been achieved. Furthermore,
although human and mammalian phenotype ontologies (HPO, MP) are being used to interpret next
generation sequencing (NGS) data [21], understanding how multiple genes contribute to a single
disease or phenotype will require resources, such as GO, that describe the cellular functions of these
gene products.
Amyloid-beta fibril deposits commonly known as plaques, and neurofibrillary tangles of
phosphorylated tau, have for decades been the pathological hallmarks of Alzheimer’s disease [22].
For many years, researchers have been studying the formation and the effects of these protein
aggregates on brain function [23–26]. However, much less attention and fewer resources have been
committed towards elucidating the underlying cellular mechanisms that drive the formation of these
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protein aggregates, or towards understanding the roles of the various cell types involved in the
maintenance of normal brain functions, including not only neurons, but also glia and the cells of
the brain microvasculature [27–29]. It is currently commonly accepted within the dementia research
communities that impairments in cellular processes that lead to disease onset can occur decades
before the first manifestations of clinical symptoms [27]. Accordingly, the research focus has been
steadily shifting from protein aggregates towards protein homeostasis and the implicated cellular
processes [30]. This has coincided with the ‘explosion’ of ‘big data’ in biomedicine. GWA and biomarker
expression studies have resulted in the generation of extensive datasets of gene loci linked to dementia
and AD [31–35]. In order to reveal the biological processes that are impaired in dementia due to changes
in expression levels and/or the regulation of these genes, high-throughput datasets can be interpreted
using GO term enrichment analysis or pathway analysis. By using the contextual information available
in GO, it would also be possible to identify the cell type(s) in which an enriched process most likely
occurred, if gene expression had been measured across the whole brain rather than in specific cell
types or individual cells [35]. Identification of the key cells that are involved is also likely to contribute
to our understanding of the cellular mechanisms underlying AD. For example, Espuny-Camacho et al.
performed GO gene set enrichment analysis on a novel chimeric model of AD, and observed an
increased expression of genes involved in myelination, and a decreased expression of genes related to
memory and cognition, synaptic transmission, and neuron projection [36]. Furthermore, two recent
studies have successfully used GO to interpret AD patient data. Xu et al. [37] investigated regional
protein expression in the brain of human AD patients, and showed the involvement of some of the
differentially expressed genes in key neurological processes, such as ‘nervous system development’
(GO:0007399) and ‘neuron projection development’ (GO:0031175). Kunkle et al. [38] described GWA
data from the largest cohort to date of late-onset AD cases, and demonstrated the involvement of
the differentially expressed genes in dementia-relevant processes such as ‘regulation of amyloid-beta
formation’ (GO:1902003), ‘tau protein binding’ (GO:0048156) and ‘activation of immune response’
(GO:0002253). Another study applied a new statistical approach that used GO with neuroimaging
phenotypes and GWA data to identify gene products that are involved in processes impaired in
disease [39]. A peculiarity of that work was the inclusion of a focussed GO annotation of 21 gene
products, the majority of which were encoded by AD-associated Mendelian genes. The 400 manual
annotations that the authors associated with these and eight other genes were included in GO
annotation files prior to carrying out the analysis. Last but not least, GO can also be used in the
reanalysis of previously published datasets, which is a potentially productive exercise, because the
availability of new GO data impacts on the information content [40].
In order to meet the urgent requirement to improve the interpretation of and draw informative
conclusions from high-throughput dementia studies, the focus of the project described here was to
provide GO annotations that capture knowledge on amyloid-beta and tau by the expert biocuration
of experimental data available through the biomedical literature (annotations resulting from this
project are assigned by ‘ARUK-UCL’). We have now completed the first phase of enhancing the GO
resource by developing new neurological GO terms and capturing the roles of proteins interacting
with amyloid-beta and tau using functional GO annotations. The curation of 40 amyloid-beta binding
proteins (i.e., proteins and protein complexes acting as amyloid-beta receptors [41]) has provided
over 2000 annotations describing the normal role of these proteins in signalling, receptor-mediated
endocytosis, and phagocytosis and/or clearance of amyloid-beta. In addition, the normal roles of
microtubule-associated protein tau and its interacting partners [42] are now also captured in GO
annotation files, following the annotation of 33 proteins and the creation of over 1700 annotations.
Here, we provide summaries of key areas of improvement, as well as an in-depth discussion of the
specific challenges that arose during this work.
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2. Materials and Methods
2.1. Community Involvement
Collaborations have been established between members of the Gene Ontology Consortium [43]
and community experts to ensure that our biocuration efforts aligned with the needs of the neuroscience
research community. Project progress and direction were discussed and, if required, revised and
updated during project meetings and through regular correspondence.
2.2. Selection of Experimental Data to Annotate
Two sets of AD-relevant high-priority human proteins and protein complexes were compiled
based on recent review articles. The first set included amyloid-beta species and their binding partners,
which have been shown to act as receptors for the amyloid-beta monomers and/or their oligomers,
and were fully based on the amyloid-beta receptors listed in the Jarosz-Griffiths el al. (2016) review [41].
The second set was a collection of proteins interacting with the microtubule-associated protein tau,
based on the review article by Guo, Noble, and Hanger (2017) [42]. This review provided a vast
list of tau-binding partners, of which 33 were selected for annotation after consultations with the
neuroscience community. Primary research articles cited in both reviews were prioritised for annotation.
The PubMed database [44] was also used to identify additional research articles that contained
experimental data describing each of the human gene products prioritised for annotation. For each
high priority protein/protein complex, PubMed searches were performed using the gene symbols and
names approved by the HUGO Gene Nomenclature Committee (HGNC) [20], as well as their synonyms.
For well-researched gene products, relevant papers were identified with secondary searches for gene
symbols and names combined with the following keywords (one at a time): ‘dementia’, ‘Alzheimer’s’,
‘Alzheimer’, ‘AD’, ‘amyloid’, ‘APP’ (amyloid precursor protein), ‘tau’, ‘MAPT’ (microtubule-associated
protein tau), ‘microtubule’, ‘neurology’, ‘neurological’, ‘neurobiology’, or ‘neurodegeneration’. If no,
or insufficient, information on the human gene product was found, orthologs, identified using the
HGNC ortholog prediction tool ‘HCOP’, were curated [20]. Peer-reviewed articles were selected
for curation based on criteria described by Denny et al. [40], i.e., (1) they contained experimental
research data; (2) the curation of any given article would result in new information being added to
the current GO annotation data associated with the prioritised gene products; (3) it was possible
to identify the species from which the gene products and/or expression constructs were derived,
crucial information enabling biocurators to assign the appropriate database identifiers to gene
products. Selected research articles were annotated fully, resulting in GO annotations of not only
the dementia-relevant high-priority gene products, but also any other proteins or protein complexes
described in those articles.
2.3. Gene Ontology Annotation of Proteins and Protein Complexes—Manual Curation Process
Primary research articles were read by skilled GO biocurators to describe the molecular functions,
biological processes, and cellular locations of the gene products and capture them using GO
terms, following established GO Consortium guidelines [40,45]. In addition, often terms from other
ontologies were included in the GO annotation extension field to provide additional contextual
information [46]. The gene product identifiers that were used in this project included UniProt
accessions [47], Complex Portal accessions [14], as well as RNAcentral accessions [48]. Specific evidence
codes were included in each biocurator-generated annotation, based on the type of experimental data
reported in the research articles (e.g., IPI: inferred from physical interaction, or IMP: inferred from
mutant phenotype), or to infer evidence from statements made in reviews (e.g., TAS: traceable author
statement [49]). GO annotations created for rodent or other mammalian gene products, based on
experimental evidence, were transferred by biocurators to human orthologs using the evidence code
ISS (inferred from sequence similarity), if 1-to-1 orthology could be confirmed. This biocuration
process was consistently applied to describe the published experimental data for each of the human
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high-priority genes and/or their orthologs. The annotations contributed by this project to the GO
resource are attributed to ARUK-UCL, and were captured using the European Bioinformatics Institute
(EBI) GO annotation tool Protein2GO [50]. All of the ARUK-UCL annotations are included in the
GO Consortium annotation files, and thus made available through various ftp sites and the GO
browsers QuickGO [51–53] and AmiGO [54,55], which are updated on a weekly and monthly basis,
respectively. Our GO annotations are also propagated to other major biological databases, including
NCBI Gene [56], Ensembl [57], UniProt [47], RNAcentral [48], and miRBase [58]. Additionally, the GO
annotation work that was completed as a part of this project contributed to the biocuration of new
Complex Portal [14] entries.
2.4. Ontology Development and Integration of Resources
The ontology editor Protégé [59] was used to generate new GO terms and, if required,
modify and/or update the existing terms. All of the ontology changes were integrated into the public
ontology version using GitHub [60]. In the QuickGO browser [51–53], GO term entries that were created
and/or updated as a result of this project include an acknowledgment for ARUK. In the AmiGO
browser [54,55], the same GO terms are identified by the source ‘GOC:aruk’ [61].
2.5. Functional Analysis of Hippocampal Proteomic Data
To identify the over-representation of GO terms in a hippocampal protein dataset (Table S8),
which was identified as differentially expressed in Alzheimer’s disease patients compared to
age-matched controls [37], the functional analysis tool g:GOSt available from the g:Profiler server [15]
was used. The analysis was undertaken on 19 November 2018, using the annotated human proteome
as the background ‘population’ set. The g:SCS method was used for computing multiple testing
correction for the GO enrichment analysis p-values, with an experiment-wide threshold of a = 0.05.
This algorithm considers the ontology structure underlying the gene sets annotated to each GO term.
The analysis used two g:GOSt preloaded GO datasets: December 2016 includes the annotation file
available in Ensembl 87 (build date December 2016) and the ontology file released 13 December 2016;
November 2018 includes the annotation file available in Ensembl 93 (build date July 2018) and ontology
file released 3 August 2018. All of the protein identifiers (Table S8) were provided by Xu et al. [37].
In addition, this dataset was also ‘seeded’ with the full list of priority proteins, in order to further
examine the impact of this annotation project; this list is subsequently referred to as the ‘priority
protein-seeded hippocampal’ list.
3. Results
3.1. Assignment of Database Identifiers
The gene products that were prioritised for Gene Ontology (GO) annotation were identified from
two key reviews [41,42] and finalised following consultations with dementia experts. Forty-nine gene
products implicated in amyloid-beta biology were prioritised for annotation; this list included
40 cellular receptors reviewed by Jarosz-Griffiths et al. [41], to which nine monomeric and oligomeric
amyloid-beta species have been shown to bind. Among the tau-interacting partners, 33 were prioritised
for annotation based on the review by Guo, Noble, and Hanger [42]; the priority list therefore includes
34 proteins (also counting tau itself). The focus of this project was the annotation of human gene
products; therefore, all of the 84 prioritised entities (76 proteins and eight complexes) are referred to
using database identifiers corresponding to human gene products (Table S1).
In order to capture amyloid-beta biology accurately, it was necessary to be able to distinguish
between amyloid-beta monomers, dimers, and oligomers, because of the different cellular effects of
monomeric amyloid-beta and its dimeric or oligomeric forms [62]. Consequently, a collaboration was
established with Complex Portal (CP) [14,63] biocurators, which resulted in the generation of 18 new
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CP entries for the different amyloid-beta monomers, dimers, and oligomers in three species (human,
rat, and mouse) (Table S2).
3.2. Gene Ontology Annotation
Research articles were selected as described in the methods section and annotated following the
established GO guidelines for manual biocuration [40]. Of the 226 PubMed-indexed articles that we
curated to capture knowledge about our 84 prioritised gene products, 191 described roles of human
gene products (Table 1, Table S3C). Twenty-five articles that had appeared in the PubMed searches and
had been read were deemed not suitable for annotation; 12 of these provided no information about the
species of the gene product(s) being annotated; six provided information about either disease, patients,
or pharmacological agents; three provided expression data without functional information; and three
were either opinion or review articles; whereas one article contained data images of insufficient quality
for a biocurator to be able to review and capture the experimental information in a GO annotation(s)
(Table S3D). Gene products were associated with relevant GO terms according to evidence provided in
the published research articles. Rather than capturing the experimental data describing only the gene
products on the priority list, all of the experimental data in each curated paper was associated with
GO terms, thus increasing the number of gene products curated, which is an efficient approach that is
often referred to as ‘full paper curation’.
Table 1. Summary of key curation statistics. (Data from QuickGO [51–53] and the Complex Portal
[14,63]—accessed: 18 October 2018—summarised in Supplementary Tables S1–S6).
ARUK-UCL GO Annotation Project: Priorities and Curation Summary Total
Prioritised human gene products 84
Prioritised human amyloid-beta-relevant gene products # 50
Prioritised human tau-relevant gene products ## 34
All species Human
PubMed identifiers (PMIDs) curated * 226 191
GO annotations ** 3886 2770
Gene products annotated ** 561 308
GO annotations associated with 84 human gene products prioritised for annotation *# n/a 2055
New Complex Portal (CP) entries *** 18 6
# For priority amyloid-beta-relevant gene products annotations, see Table S1A; ## For priority tau-relevant gene
products annotations, see Table S1B; * For PMIDs annotated by ARUK-UCL, see Table S3C; ** For all of the
ARUK-UCL annotations and details of gene products, see Table S3A; *# For ARUK-UCL annotations to prioritised
gene products, see Table S4 and filter ‘Assigned By’ A→ Z to group ‘ARUK-UCL’ annotations together; *** For details
about new CP details, see Table S2.
Through our whole-paper curation approach, a total of 3886 GO annotations have been
contributed for a total of 561 gene products, including proteins (UniProt [47,64] identifiers),
microRNAs (RNAcentral [48] identifiers), and protein complexes (Complex Portal [14,63] identifiers)
as a part of this ARUK-UCL annotation initiative. Among these, 2770 GO annotations were associated
with 308 human gene products, and 2055 were associated specifically with the proteins and complexes
prioritised for annotation (Table 1, Tables S1–S4); based on data from QuickGO, accessed 17 August 2018).
The annotations that we have provided ensure that the role of these gene products in
dementia-relevant processes is captured; overall, this project created just over a quarter of the
annotations now associated with these 84 protein and complex records. For example, several of
the priority genes (such as APP, APOE, FYN, and HSP90AB1) had over 200 associated GO annotations
prior to the start of this project, but few of these described neurological processes. Our work has
resulted in 526 new annotations to neurological GO terms for all but one of the prioritised gene
products (Figures 2 and 3, Table S5), capturing their dementia-relevant roles in neurological processes.
For one, SCARB2, no evidence to support the association of a neurological or amyloid-related GO term
was identified in the published literature.
Overall, approximately two-thirds (526 of the 834) of the neurological, amyloid-beta,
or tau-relevant GO terms, which are now associated with 84 of our prioritised gene products,
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were created by the ARUK-UCL initiative. Previously, only 49 of these gene products were associated
with neurological process, a neuronal cellular location, or a molecular function relevant to amyloid-beta
or tau biology (Figures 1 and 3, Table S5). In summary, the ARUK-UCL contribution greatly increased
the number of our prioritised gene products being associated with neurological process GO terms,
e.g., ‘amyloid-beta clearance’ and ‘learning or memory’, as well as localising to neuronal structures,
including axons, dendrites, and their compartments.
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Figure 3. A histogram of all the manu lly cur ted neurological a n tations for the prioritised
tau-relevant human gene products, including annotations contributed by ARUK-UCL as well as
by other groups. Data for this figure was derived from Table S5.
3.3. Gene Ontology Development and Revisions
3.3.1. New and Revised Gene Ontology Terms
As the literature curation progressed, new GO terms were needed to represent normal cellular
functions or compartments altered in dementia. In some cases xi ting GO terms were also revised
and updated with recent knowledge, or with synonyms that were useful for biocuration and literature
mining (Table S6). For instance, 10 new GO terms have been added to the ‘neuron projection
morphogenesis’ biological process branch, and numerous corresponding ‘neuron projection’ cellular
component terms have been revised. In addition, new molecular function and biological process
terms have been added to lipoprotein particle-related terms. Moreover, revisions have been made
to ‘synaptic vesicle endocytosis’, and new child terms, for this GO term, have been added. Overall,
84 GO term entries were curated as part of this project; of these, 71 new GO terms were created,
and 13 existing GO terms were modified (Table S6). Sixty-eight of these new, or modified, GO terms
represent biological processes; 15 are cellular component terms, and one is a molecular function term.
These terms were used to curate proteins and protein complexes prioritised for annotation (Table S1)
due to their association with dementia. Details of these new additions and revisions can be tracked on
the GitHub Gene Ontology pages [60] by filtering issues marked with ‘ARUK-UCL’ labels.
3.3.2. Revisions and Development of Neuron Projection Gene Ontology Branches
The revision and modification, as well as creation, of GO terms describing neuron
projection-relevant processes are key contributions of this project, and were undertaken to improve
the representation of dementia-relevant brain biology. Axons and dendrites, i.e., pre-synaptic
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and post-synaptic neuron projections, enable neuron-to-neuron signalling through synapses,
whereas synaptic plasticity, which is dependent on the structural and functional integrity of synapses
between neuron projections, is key for memory formation and learning [65]. Early in this project,
the need to revise the ‘neuron projection’ GO domain was identified in order to capture full functional
information that describes how the binding of amyloid-beta to receptors on pre-synapses and
post-synapses or the presence of phospho-tau neurofibrillary tangles in synaptic compartments may
lead to the modulation of synaptic plasticity [66,67].
Literature curation did confirm the involvement of many of the prioritised gene products
(Table S1) in ‘neuron projection development’ and ‘neuron projection organisation’. This resulted
in 33 experimental, or orthology-based, GO annotations applying terms descended from ‘neuron
projection development’ (Figures 1 and 4); all of these annotations were made to the GO terms created,
or revised, by ARUK-UCL. Biocurators from the Rat Genome Database (RGD) [68] also contributed
to the development of this GO branch or terms descended from ‘neuron projection development’ by
requesting regulation terms of ‘neuron projection arborisation’.
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Figure 4. Descendants of bi logical process ‘ne rojection development’ GO t rm created or
modified, as a result of this ARUK-UCL project. Ontology: The blue box represents the ancestor
term ‘neuron projection development’ (GO:0031175). The yellow boxes represent the terms created,
or modified, as a result of the ARUK-UCL project (Table S6); the majority of these are new terms;
two terms were modified: ‘dendrite development’ (GO:0016358) and ‘dendrite morphogenesis’
(GO:0048813). The white boxes represent related terms in the ontology; no changes have been made
to these terms. Arrows indicate the following ontology relationships: black—is_a, blue—part_of,
yellow—regulates, green—positively_regulates, red—negatively_regulates. Annotations: Each green
box provides information about gene products associated with the GO term in the yellow box, which it
overlaps (data from QuickGO [51–53], accessed: 20 November 2018). For total numbers of annotations,
provided in the green boxes, the following QuickGO filter was used: ‘GO terms→ Options→ Use
these terms as an exact match’; an additional filter ‘Evidence→ ECO:0000352: evidence used in manual
assertion’ was then applied to retrieve the numbers and examples of manually asserted annotations;
these include annotations contributed by ARUK-UCL and by other groups. Examples of annotations
including GO terms shown above are presented in Figure 1.
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New additions and revisions of the biological process terms involving ‘neuron projection’
naturally led to revisions of the related cellular component terms (Figure 5). In parallel, revisions of the
dendrite-related component terms were additionally prompted by RGD requests for new GO terms to
describe ‘primary dendrite’, ‘distal dendrite’, and ‘dendritic spine origin’. This also led to a revision of
the ‘dendritic tree’ (GO:0097447), ‘dendritic branch’ (GO:0044307), ‘dendrite’ (GO:0030425), and ‘basal
dendrite’ (GO:0097441) terms; specifically, of their definitions and relations to other GO terms in the
ontology. Among others, several of the prioritised gene products (Table S1) have been associated with
descendants of the ‘neuron projection’ GO term (Figure 5, green boxes).
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Figure 5. Descen ce lular component ‘neuron projection’ GO terms created or modified,
as a result of this ARUK-UCL project. Ont logy: The blue box represents the ancestor term ‘neuron
projection’ (GO:0043005). The yellow boxes represent the terms created, or modified, as a result of
the ARUK-UCL project (Table S6). The majority of these are new terms; five terms were modified:
‘dendritic tree’ (GO:0097447), ‘dendrite’ (GO:0030425), ‘basal dendrite’ (GO:0097441), ‘dendritic branch’
(GO:0044307), and ‘growth cone’ (GO:0030426). The white boxes represent related terms in the
ontology; no changes have been made to these terms. Arrows indicate the following ontology
relationships: black—is_a, blue—part_of. Annotations: Each green box provides information about
the gene products associated with the GO term in the yellow box, which it overlaps (data from
QuickGO [51–53]—accessed: 20 November 2018). For the total numbers of annotations, which is
provided in the green boxes, the following QuickGO filter was used: ‘GO terms→ Options→ Use
these terms as an exact match’; an additional filter ‘Evidence→ ECO:0000352: evidence used in manual
assertion’ was then applied to retrieve the numbers and examples of manually asserted annotations.
The green boxes include examples of gene products annotated by ARUK-UCL and other groups.
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A major change to the cellular component ‘neuron projection’ branch, which resulted from the
ARUK-UCL literature curation and RGD new term requests, concerned the conflicting definitions
of ‘dendrite’ and ‘dendritic tree’, which previously stated that both of these neuron projections were
branched, suggesting that both terms referred to the same structure. These definitions have now
been modified in order to distinguish the terms from each other. The first sentence in the ‘dendrite’
definition has been changed from ‘a neuron projection that has a short, tapering, often branched
morphology . . . ’ to ‘a neuron projection that has a short, tapering, morphology . . . ’. Whereas,
the ‘dendritic tree’ definition now includes the sentence, ‘the entire complement of dendrites for a
neuron, consisting of the primary dendrite and all its branches’. In addition, it was also necessary
to revise the relationships between the different descendants of ‘dendritic tree’ as well as with its
parent terms (Figure 5). The GO term ‘dendritic tree’ now has the is_a parent ‘neuron projection’,
and the part_of parent ‘somatodendritic compartment’, and the direct is_a parent ‘cell part’ has been
removed. In contrast, the term ‘somatodendritic compartment’ is no longer a direct part_of the parent
of ‘dendrite’, which instead has the is_a parent ‘plasma membrane-bound cell projection part’ and the
part_of parent ‘dendritic tree’.
Furthermore, as a result of the ARUK-UCL literature curation, even more specific ‘dendrite’ terms
were added, including ‘apical distal dendrite’ (GO:0150014), ‘apical proximal dendrite’ (GO:0150015),
‘basal distal dendrite’ (GO:0150016), and ‘basal proximal dendrite’ (GO:0150017). The creation of these
new terms was prompted by the necessity to capture the specific neuronal localisation of the MAP2
gene product, which was prioritised for annotation of tau-relevant biology (Table S1), to ‘apical distal
dendrite’ (Figure 6). The RGD also requested the new term ‘distal axon’ (GO:0150034), which led to
revisions of the axonal ‘neuron projection’ GO branch and resulted in the modification of definition
and relations of ‘growth cone’ (GO:0030426) (Figure 5).
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Figure 6. Rat Map2 and human MAP2 GO annotations to ‘apical distal dendrite’ (GO:0150014) assigned
by ARUK-UCL. (Screenshot from QuickGO [51–53]—accessed: 31 October 2018).
3. . . Concerted Effort of GO Consortiu i i s of ‘Synaptic Vesicle Endocyto is’
The ‘synaptic vesicle endocytosis’ rigina ly defined as dependent on clathrin;
however, not all synaptic vesicle en t ri - ediated [69,70]. Some of the GO
annotations that had be n made to ‘sy ti si l cytosis’ may not have been based on
clathrin-mediated mechanisms; the gene products may have been involved in an alternative mechanism
of ‘bulk synaptic vesicle endocytosis’. Consequently, GO biocurators agreed to review 97 experimentally
evidenced annotations to ‘synaptic vesicle endocytosis’ (GO:0048488) and its child terms, including
‘(positive/negative) regulation of synaptic vesicle endocytosis’ terms. At least a third of the ‘synaptic
vesicle endocytosis’ annotations lacked experimental evidence that confirmed the involvement of
clathrin in the curated data. There was unanimous agreement among the GO contributors that the
definition should be made more general, in order to encompass the mechanisms of synaptic vesicle
import independent of clathrin. Additionally, in order to allow for more specific annotations, we created
two new child terms of ‘synaptic vesicle endocytosis’ (GO:0048488): ‘clathrin-dependent synaptic
vesicle endocytosis’ (GO:0150007) and ‘bulk synaptic vesicle endocytosis’ (GO:0150008). These terms
are distinguished by their definitions: GO:0150007: ‘Clathrin-dependent endocytosis of presynaptic
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membrane regions comprising synaptic vesicles’ membrane constituents. This is a relatively slow
process occurring in the range of tens of seconds.’; and: GO:0150008: ‘Endocytosis of large regions
of presynaptic membrane after intense stimulation-mediated fusion of multiple synaptic vesicles.
Bulk endocytosis is triggered by high loads of membrane addition through exocytosis of synaptic
vesicles and elevated concentration of calcium in the presynapse’.
3.3.4. Challenges Related to Emphasis on ‘Normal’ Processes
The GO has been designed to capture only ‘normal’ processes, functions, and cellular locations.
When annotating gene products relevant to a specific disease, this presents a major challenge, as it is
necessary to determine what is ‘normal’. For the annotation of AD-relevant gene products, this was a
significant hurdle, particularly when capturing the roles of amyloid-beta species, including monomers,
dimers, and oligomers (Table S2). This annotation project recognised that ‘ageing’ (GO:0007568) is
a normal physiological process and consequently teased out data that described the association of
dementia with ageing and the involvement of amyloid-beta in AD pathology [71–75]. Furthermore,
we decided that it was necessary to capture the evidence that amyloid-beta (as well as tau) has
normal physiological roles at the synapse [66,67], and, consequently, the normal roles of amyloid-beta
complexes have been annotated as part of this project [62,66,76]. GO annotations describing age-related
effects associated with amyloid-beta dimers and/or oligomers were also captured [71–75].
On the other hand, the literature review also revealed that there are some types of amyloid-beta
oligomers, specifically the so-called amyloid-beta globulomers [77,78] and amylospheroids [79,80],
which have only ever been observed in pathological cases; consequently, their roles have not been
captured in GO.
3.4. Impact of Improved GO Annotation on Data Analysis
In order to evaluate the impact of this annotation project on high-throughput data interpretation,
we undertook a functional analysis (Tables S7–S10) of a hippocampal proteomic dataset [37].
This dataset identified the hippocampal proteins that were differentially expressed in AD versus
age-matched controls (Table S8), and analysed using the current (November 2018) GO annotation and
ontology files preloaded in g:GOSt [15] as well as archived files (December 2016).
The previous analysis by Xu et al. [37] had identified a variety of enriched pathways in this dataset,
including innate immune response, carbohydrate metabolism, and a variety of specific signalling
pathways, such as those involved in the regulation of apoptosis and cell cycle, and pathways leading
to neurotransmitter synthesis. Both our 2016 and 2018 g:GOSt analyses also identified these processes,
as well as other neurologically-relevant terms such as synaptic signalling and axonal transport
(Table S7). By grouping the enriched GO terms into broad classes (Tables S9 and S10), it was apparent
that the majority of the enriched terms were associated with transport (i.e., localisation, transport,
vesicle and vacuole terms), as demonstrated, for instance, by annotations to microtubule-related terms
(Table S7, filter on column A by ‘microtubule’), in addition to metabolism and the organisation and
biogenesis of specific cellular components.
A comparison between the GO terms enriched using the 2016 versus the 2018 files (Table S11)
demonstrates how the continued contribution of annotations to the GO Consortium resource and the
revision of the ontology continues to impact the analysis of high-throughput datasets. The 2016 to 2018
comparison identified a difference between these analyses, with 84 terms identified only in the 2016
analysis, and 181 enriched GO terms only present in the 2018 analysis (Table S11A, column F, rows 5, 7,
14). Of particular note is the increase in the number of hippocampal proteins associated with immune
system terms: using the 2016 GO files, only antigen presentation terms were identified as dysregulated
in the hippocampus, while the 2018 analysis identified that 23% of dysregulated hippocampal proteins
may be contributing to an immune response, with a suggestion that neutrophils are mediating this
effect (Table S7, filter on column E by ‘immune system process’). Similarly, the GO term ‘neuron death’
Genes 2018, 9, 593 14 of 24
is only enriched when using the 2018 GO files, with 4% of hippocampal proteins associated with this
term (Table S7, filter on column E by ‘neuron death’).
To demonstrate the impact of the ARUK-UCL project on functional analysis (Tables S7–S10),
we repeated the above analyses using the same hippocampal protein list, but with the addition of
all the proteins that we had prioritised for annotation (the ‘priority protein-seeded hippocampal’
list). However, 10 of these proteins (CLU, DCTN1, FYN, GSK3A, GSK3B, HSP90AB1, HSPG2, PIN1,
PPP2CA, and ROCK2) were present in both the hippocampal protein and priority protein lists (Table S8).
While the same 633 GO terms can be seen as enriched in both the 2016 and 2018 analyses, for this
‘priority protein-seeded hippocampal’ list, there are 356 GO terms that are only enriched using the
2018 GO files (Tables S10 and S11). As the ARUK-UCL project has used many of the terms as only
enriched in the 2018 analysis to capture the role of dementia-relevant gene products, it is likely
that some of these differences can be attributed to this project. Notably, amyloid-beta clearance and
neuroinflammation-relevant GO terms are enriched in the 2018 analysis, but not the 2016 analysis
(Table S7, filter on column E by ‘amyloid-beta clearance’ and ‘neuroinflammation’). An investigation
into the source of the ‘amyloid-beta clearance’ annotations associated with human proteins confirms
that the ARUK-UCL project is responsible, either directly or indirectly (through the annotation of an
ortholog), for all but one of these annotations (data from QuickGO—accessed: 20 November 2018).
In addition, many of enriched GO terms that are identified only in the 2018 files with this ‘priority
protein-seeded hippocampal’ list, are relevant to signalling and transport, reflecting the role of many
of our priority proteins in these areas.
4. Discussion
Controlled biomedical vocabularies, or ontologies, have been used to semantically capture and
describe AD-specific knowledge to enhance its sharing and exchange, as well as to aid collaborative
funding and research efforts [81–84]. The use of ontologies has also been suggested to help with
the prioritisation of genes for neuroimaging studies [39], as well as with the diagnosis of cognitive
impairments [85]. With one exception [6], these vocabularies have been intended to capture and describe
the domain of knowledge specific to disease, or phenotype, and not normal physiological processes.
Here, we used Gene Ontology (GO), a controlled biological vocabulary, to describe the normal
roles of gene products implicated in AD and dementia. The advantage of GO is that it is a
well-established and regularly maintained resource, which is commonly used for enrichment analyses
across biomedical fields [40,86–88] and even in clinical practice [89]. In addition, during curation,
we focus on a specific biological area, such as amyloid-beta receptors, and we annotate whole research
articles using GO to capture the roles of all the gene products described. Thus, through our project,
we enhanced GO more broadly, which not only benefits the Alzheimer’s disease researchers, but also
the biomedical research communities overall.
4.1. Cellular Events Underlying Dementia
Amyloid-beta plaques and phospho-tau neurofibrillary tangles (NFTs) are the pathological
hallmarks of dementias, and historically, they were believed to be the underlying causes of the dementia
associated with AD [22,90–92]. It is now understood that in terms of amyloid-beta, AD pathology is
exacerbated by its oligomers (amyloid-beta intermediates formed from the monomeric peptides
prior to sedimentation into plaques) rather than the plaques, and the oligomers’ neurotoxicity
depends on their concentrations and/or the presence of specific forms, such as globulomers
or amylospheroids [71–75,77–80]. Whereas, phospho-tau has been demonstrated to contribute to
dementia pathology due to its prion-like seeding activity [93–96], which allows the aberrantly
phosphorylated tau aggregates to spread to as-yet unaffected brain regions, thus advancing the
clinical symptoms. Yet, in recent years, scientific research has generated evidence, which demonstrates
that the formation of these neurotoxic protein aggregates results from prior impairments in underlying
cellular processes [27]. When these cellular brain processes are malfunctioning, this eventually leads
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to disruptions in protein homeostasis and the clinical manifestations of dementia [30]. Consequently,
the plaques and/or NFTs that are characteristic of the brain pathology associated with advanced-stage
dementia are currently believed to be the by-products of compensatory processes, which become
activated in the brain at the cellular level to address the imbalances underlying the disease [30,97].
Therefore, until disease progression and its mechanisms are fully elucidated and understood,
it should not be assumed that the fibrils of amyloid-beta and/or phospho-tau cause dementia,
or specifically AD. Studies on post-mortem brain tissue sections of healthy controls revealed vast
deposits of amyloid-beta in the brain despite a lack of symptoms [98]. Despite findings from animal
models and cell culture studies, it is currently understood that the onset of dementia pathology occurs
decades before the first symptoms manifest themselves [27], supporting the hypotheses that protein
homeostasis mechanisms and other cellular functions begin to deteriorate long before amyloid-beta
deposition and NFT formation become apparent [30,97]. Furthermore, research focus has been shifting
to other cell types in addition to neurons, specifically glia and the cells of the brain vasculature,
as evidence suggests that impaired communication between these cell types and neurons also promotes
disease progression [27].
This very tight link of amyloid-beta and phospho-tau with dementia pathology and AD has
posed major challenges for this GO annotation project. The purpose of GO is to capture the ‘normal’
physiological roles of gene products, not their roles in disease pathology. Although the impact of
amyloid-beta and phospho-tau can be captured using phenotype ontologies, a combined disease
and GO database that applies GO terms in the context of a pathological environment is currently
missing from the resources that are available to the biomedical research communities. The question
of what is ‘normal’, especially in the context of amyloid-beta and a lack of clear boundaries between
ageing-related biological aspects and disease processes, still exists [98]. Therefore, the first goal of
this project was to establish whether any roles of amyloid-beta, and, more importantly, its multimeric
forms, could be captured using GO.
A literature search revealed that in normal physiological conditions, amyloid-beta levels are
regulated by neuronal activity [99–101], and that amyloid-beta in turn modulates synaptic plasticity in
neural circuits [66,102]. Amyloid-beta has also been shown to positively affect neuronal growth [62,76].
In addition, scientific findings have demonstrated that the effects of amyloid-beta are age-related [71–75].
‘Ageing’ (GO:0007568) is a normal physiological process involving the ‘loss of functions such as
resistance to disease, homeostasis, and fertility, as well as wear and tear’, i.e., aspects that are directly
translatable to impairments in cellular processes underlying dementia. Based on this published
evidence, we curated 18 new Complex Portal (CP) entries for physiologically occurring human,
mouse, and rat amyloid-beta dimers and oligomers (Table S2), and we annotated their roles using GO.
Our annotations will enable users to extract a list of the proteins known to interact with amyloid-beta.
Furthermore, the detection of dysregulated amyloid-beta-interacting proteins within ‘-omics’ datasets
will be facilitated.
In addition to amyloid-beta monomers, dimers, and oligomers as well as tau, 74 gene products
were prioritised for GO annotation, following dementia experts’ advice, and these included proteins
and protein complexes interacting with either amyloid-beta or tau (Table S1). As we take a
process-focussed approach to curation, we annotate research articles fully and capture the roles of all
of the gene products that were investigated and described in any given research paper. Consequently,
the total number of gene products annotated in the context of amyloid-beta and tau biology was 561,
of which 308 were human, i.e., far more gene products were annotated than those in the prioritised
list. The majority of the annotated human gene products were proteins, but some protein complexes
(including six types of amyloid-beta complexes and two of their interacting partners prioritised
for annotation) and two microRNAs were also annotated as a part of this project (Table S3A).
These 561 gene products have been associated with 3886 GO terms, based on published evidence;
of these, 308 human gene products have been associated with 2770 GO terms (Table 1). Hence,
by contributing these new ARUK-UCL annotations, we have greatly expanded the representation
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of dementia-relevant knowledge in GO, incorporating new GO annotations for four (gene products
of CLU, PICALM, APOE, and BIN1) of the 21 gene products previously annotated as a part of the
AD-focussed initiative at the University of Toronto [39]. Furthermore, prior to this project, there were
no GO terms associated with either the complement receptor type 3 complex (CP-1826), or the amylin
receptor 3 complex (CP-3187), which are both products of genes prioritised for annotation (Table S1).
As a result of this project, there are currently 14 and 21 annotations, respectively, for these two
complexes in the GO database (data from QuickGO, accessed: 30 October 2018).
Collectively, the 3886 annotations describing the normal physiological roles of the prioritised
gene products interacting with either amyloid-beta or tau, as well as other proteins, complexes,
and microRNAs implicated in processes impaired in AD, have greatly expanded the representation of
dementia-relevant neurological processes, functions, and cellular compartments in GO. Over the
past two years, increasing numbers of annotations have been included in the GO Consortium
annotation files, and we have demonstrated that this improves the interpretation of AD proteomic
data (Tables S7–S10). Our focus on dementia-relevant processes has contributed to this, for example,
by creating ‘regulation of neuron death’ annotations to some of the prioritised proteins. By capturing
published knowledge about these processes, we are providing the AD and dementia research
communities with a resource that is potentially useful for diagnostic purposes and/or disease
prevention. The annotation of dementia-relevant gene products involved in these early cellular
processes makes knowledge available for analyses of clinical or experimental datasets related to
cognition, which could help delineate the biological pathways that can be targeted for diagnostic or
preventive purposes decades prior to the onset of this debilitating disorder.
4.2. Representing Neurobiology Using Gene Ontology
The dementia-focussed ARUK-UCL project described here and the University of Toronto GO
annotation project [39] are not the only GO initiatives intended to improve the representation of the
neurobiological knowledge domain in GO. Our team was previously funded to capture the knowledge
relevant to Parkinson’s disease (annotations assigned by ParkinsonsUK-UCL) [40,103,104], and we
have also participated in a large multi-center collaborative effort to curate published information about
the synapse (annotations assigned by SynGO and SynGO-UCL) [105]. Furthermore, our interactions
with other members of the GO Consortium, including biocurators of model organism resources,
have been very important for the success of this project, especially in the context of GO development
and revisions.
Overall, the project has resulted in the addition of 71 new GO terms to the ontology (Table S6;
data from AmiGO2, accessed: 30 May 2018). These GO terms were created for the annotation of research
findings involving the prioritised gene products, but many of them have also been used for manual
annotation by other curation teams, as well as included in automatic annotation approaches [64].
For instance, the ARUK-UCL-contributed ‘neuron projection arborisation’ (GO:0140058) GO term has
been used in a total of 90 annotations, of which 11 are manual annotations, although only three of these
annotations resulted from this project (data from QuickGO, accessed: 11 October 2018). This shows
that other members of the GO Consortium are also using GO terms resulting from this project for
the annotation of their biological domains. This is just one example of how work resulting from one
focussed GO annotation initiative aids the work of other curation teams, and thus benefits wider
communities of researchers who use GO in their data analyses.
In addition to contributing new GO terms, work on this project also led to the revision of thirteen
previously existing GO terms, as well as the logical relations between them (Table S6). A number of
these revisions were prompted because new terms were required to annotate gene products prioritised
in this project. However, the revisions were improved by additional new term requests and suggestions
from biocurators at the Rat Genome Database (RGD). GO branches that were revised and enhanced
through these concerted efforts organised the knowledge about descendants of the biological process
‘neuron projection development’ (GO:0031175) GO terms (Figure 4) and the cellular component
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‘neuron projection’ (GO:0043005) GO terms (Figure 5). These improvements to the ontology are crucial
for the accurate representation of the dementia-relevant neurobiological domain using GO. In fact,
this project has resulted in 57 annotations to ‘neuron projection development’, or one of its descendant
terms, and 249 annotations to ‘neuron projection’, or one of its descendants (data from QuickGO,
accessed: 11 October 2018).
A close collaboration is of even greater importance when ontology revisions need to be
coordinated with revisions of existing GO annotations. This was demonstrated when it became
apparent that updates to the annotations associated with the GO term ‘synaptic vesicle endocytosis’
were required. ‘Synaptic vesicle endocytosis’ was originally defined as a clathrin-mediated process;
however, FlyBase [106] biocurators identified that not all of the endocytic processes occurring in
the synapse depend on clathrin. Prior to this, there had been a total of 97 experimentally evidenced
annotations to ‘synaptic vesicle endocytosis’ assigned by 10 different curation groups. Thus, in order to
reach a GO Consortium-wide consensus about whether to broaden the definition of this term to include
endocytic mechanisms not requiring the involvement of clathrin, or whether to update the GO term
name to ‘clathrin-dependent synaptic vesicle endocytosis’, it was crucial to first review the existing
annotations to determine whether the experimental support did indeed provide evidence for clathrin
mediating the endocytosis. As a result of this combined effort, and following consultations with
synapse biology experts, a decision was made to broaden the definition of the existing ‘synaptic vesicle
endocytosis’ GO term, and to add two more descriptive child GO terms to capture information about
the specific types of synaptic endocytosis. Biocurators then updated the annotations using these new
terms if there was sufficient experimental data to support this.
Overall, the new GO terms resulting from this project have broadened the representation of the
neuroscience domain in GO, making a greater number of terms available to biocurators for the GO
annotation of neurological concepts. In addition, ontology revisions helped to ensure the highest
possible quality of this resource by reviewing existing annotations and ontology entries describing
neurobiological concepts, and by ensuring that they are accurately defined and appropriately related
to each other in the GO term hierarchy.
5. Conclusions
In order to understand the cellular processes underlying Alzheimer’s disease and other dementias,
numerous transcriptomic, proteomic, and genome-wide association (GWA) studies have been
conducted [2,4–6]. The analyses and interpretation of results from such high-throughput analyses
greatly rely on functional annotation data provided by resources such as GO [10], KEGG [12],
or Reactome [11], as well as on appropriate experimental design, the analysis tools used, and the
settings applied. Among these, analyses performed using the latter two resources can yield informative
results only if the dataset being analysed contains gene products with known functions in biological
pathways. In contrast, the GO resource captures the cellular roles and locations of a higher number of
gene products, even when the molecular functions of gene products are unknown. Therefore, GO is
suitable for analyses of datasets that are likely to contain gene products whose specific function and
biological role have not yet been fully investigated. Yet, prior to this project, the applicability of
GO for the analysis of dementia-relevant neurological datasets was limited, because there had been
no previous efforts to comprehensively annotate gene products with roles in this biological domain,
with the exception of a project undertaken by the University of Toronto [39] that focussed only on a
small group of AD risk genes.
So far, our commitment to improving the GO resource for dementia-relevant research has focussed
on amyloid-beta, the microtubule-associated protein tau and its interacting partners, as described
here. Our ongoing and future efforts aim to capture the biology of neuroinflammatory processes, e.g.,
the activation of glial cells in response to an inflammatory stimulus [107], the functional information
about proteins involved in these processes, as well as knowledge about the microRNAs that regulate
the expression of these proteins. As an initial focus, we have been annotating the roles of proteins
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involved in the biology of glial cells, primarily microglia; the lists of proteins that we have prioritised
for annotation are available on our website [108]. Additionally, we have begun the GO annotation
of microRNAs involved in the regulation of the expression of these proteins, primarily focussing on
capturing experimentally evidenced microRNA–target interaction.
Through our systematic and focussed development of GO terms relevant to dementia and revision
of previously existing neurological GO terms, as well as by detailed manual GO annotation of gene
products implicated in dementia, we have enhanced the suitability of the GO resource for analysis of
neurological ‘-omics’ datasets. These ongoing and future contributions to the GO resource will help
provide insights into the molecular bases of dementia, thus supporting the development of treatments
and of tools for early diagnosis.
All of the GO terms and annotations are freely available and can be downloaded from
QuickGO [51–53] and AmiGO [54,55]. Information on protein complexes can be found at the Complex
Portal [63,109]. We encourage scientists to become involved in the GO annotation of their own
papers and/or gene products of interest. In order to contribute to GO, please contact UCL Functional
Gene Annotation [108], GOA (https://www.ebi.ac.uk/GOA/contactus) [110] or the GO Consortium
(http://geneontology.org/page/contributing-go) [111].
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